Ignite Creation Date:
2025-12-24 @ 11:41 PM
Ignite Modification Date:
2025-12-25 @ 9:32 PM
Study NCT ID:
NCT04803851
Status:
UNKNOWN
Last Update Posted:
2023-06-22
First Post:
2021-02-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Sponsor:
Peking Union Medical College Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-12
Start Date Type:
ACTUAL
Primary Completion Date:
2024-02-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-06-29
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-23
First Submit QC Date:
None
Study First Post Date:
2021-03-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-18
Last Update Post Date:
2023-06-22
Last Update Post Date Type:
ACTUAL